Flagship explainer
What drives BridgeBio Pharma, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$733M | FY2025 |
| |
| Income before tax | −$733M | FY2025 |
|
| Operating income | −$523M | FY2025 |
|
| $502M | FY2025 |
| |
| Ending assets | $936M | FY2025 |
|
| Beginning assets | $919M | FY2024 |
|
| −$2.1B | FY2025 |
| |
| −$1.5B | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0000950170-25-024119
- SEC filingFiling detailsAccession 0001743881-26-000009